Coherus BioSciences Management
Management criteria checks 3/4
Coherus BioSciences' CEO is Denny Lanfear, appointed in Sep 2010, has a tenure of 14.17 years. total yearly compensation is $5.90M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth $937.64K. The average tenure of the management team and the board of directors is 2.8 years and 3.3 years respectively.
Key information
Denny Lanfear
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 16.7% |
| CEO tenure | 14.2yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$450k |
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$983k | -US$238m |
| Sep 30 2023 | n/a | n/a | -US$217m |
| Jun 30 2023 | n/a | n/a | -US$264m |
| Mar 31 2023 | n/a | n/a | -US$271m |
| Dec 31 2022 | US$7m | US$945k | -US$292m |
| Sep 30 2022 | n/a | n/a | -US$279m |
| Jun 30 2022 | n/a | n/a | -US$230m |
| Mar 31 2022 | n/a | n/a | -US$210m |
| Dec 31 2021 | US$9m | US$885k | -US$287m |
| Sep 30 2021 | n/a | n/a | -US$232m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$7m | US$857k | US$132m |
| Sep 30 2020 | n/a | n/a | US$162m |
| Jun 30 2020 | n/a | n/a | US$181m |
| Mar 31 2020 | n/a | n/a | US$145m |
| Dec 31 2019 | US$5m | US$751k | US$90m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$4m | US$702k | -US$209m |
| Sep 30 2018 | n/a | n/a | -US$196m |
| Jun 30 2018 | n/a | n/a | -US$196m |
| Mar 31 2018 | n/a | n/a | -US$208m |
| Dec 31 2017 | US$3m | US$656k | -US$238m |
Compensation vs Market: Denny's total compensation ($USD5.90M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Denny's compensation has been consistent with company performance over the past year.
CEO
Denny Lanfear (69 yo)
14.2yrs
Tenure
US$5,897,924
Compensation
Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.2yrs | US$5.90m | 0.99% $ 937.6k | |
| Former Interim CFO | 2.2yrs | US$1.07m | 0.023% $ 21.7k | |
| Chief Commercial Officer | 3.8yrs | US$1.93m | 0.071% $ 66.8k | |
| Chief Technical Officer | 2.8yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive Vice President of General Counsel | less than a year | no data | no data | |
| Vice President of Communications | no data | no data | no data | |
| Executive Vice President of Corporate Development | 1.8yrs | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Senior Vice President of Commercial Analytics & Trade | no data | no data | no data | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Chief Medical Officer | 2.7yrs | no data | no data |
2.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: CHRS's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.2yrs | US$5.90m | 0.99% $ 937.6k | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Lead Independent Director | 12.8yrs | US$228.69k | 0.087% $ 82.1k | |
| Independent Director | 3.8yrs | US$198.69k | 0.0076% $ 7.2k | |
| Independent Director | 10.5yrs | US$65.00k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$186.19k | 0% $ 0 | |
| Member of Strategic Advisory Board | 1.2yrs | no data | no data | |
| Independent Director | 2.5yrs | US$188.69k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$183.69k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$193.69k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
60yo
Average Age
Experienced Board: CHRS's board of directors are considered experienced (3.3 years average tenure).